Fins Neuro (1-516-478-8304)
  • Home
  • About Us
  • Contact Us
  • News
  • Denomics
Clinical Resources

A New Approach to Dementia

1. With over 100 years of research, significant disease modifying treatments for dementia have not been found 2.Dementia is much more complex than other medical conditions due to slow onset over many years, difficulties making the diagnosis and the difficulty of making model systems. 3.I feel it is now the time to take a new approach with: A. Large scale partnerships between academics, companies, govermental authorities working together with the general public. B. The current model of individual research groups has not been successful as the amount of data that can be collected and ideas that can be tested is necessarily limited. Opening coordinated research opportunities to a wider group will be essential. 4. The paper attached below provides some specific Challenges to the the field. It is meant to foster discussion. 5. Please feel free to share the paper and to provide ideas regarding implementation or significant problems
CHALLENGES IN DEMENTIA

Diet and Dementia

Only with large amounts of data and detailed data regarding food intake will bwe succeed in unravelling these connections. There is conflicting information on the relationship between diet and dementia. Thepurposes of this pilot study were twofold. First, to use publicly available data regardingfood consumption (United Kingdom Family Food), dementia, risk and demographicfactors to find relationships between the consumption of various foods to dementiaprevalence. The second purpose was to identify elements of study design that hadimportant effects on the results. Multiple analyses were performed on different datasets derived from the existing data. Statistical testing began with univariate correlationanalyses corrected for multiple testing followed by global tests for significance.Subsequently, a number of multivariate techniques were applied including stepwiselinear regression, cluster regression, regularized regression, and principal componentsanalysis. Permutation tests and simulations highlighted the strength and weakness ofeach technique. The univariate analyses demonstrated that the consumption of certainfoods was highly associated with the prevalence of dementia. However, because ofthe complexity of the data set and the high degree of correlation between variables,different multivariate analyses yielded different results, explainable by the correlations.Some factors identified as having potential associations were the consumption of rice,sugar, fruit, potatoes, meat products and fish. However, within a given dietary categorythere were often a number of different elements with different relations to dementia. Thispilot study demonstrates some critical elements for a future study: (1) dietary factorsmust be very narrowly defined, (2) large numbers of cases are needed to supportmultivariable analyses. (3) Multiple statistical methods along with simulations must beused to confirm results.
DEMENTIA AND DIET

Using Denomics

The role of massive demographic databases in intractable illnesses: Denomics for dementi
Fresno Institute Of Neuroscience
Enhancing NeuroScience Care through Collaboration and Diligence
Services
  • Clinical Neurology Care
  • Neurophysiology Services
  • Research
  • Education
  • Consulting
  • Manuscript Preparation
Location
Headquarters 1558 E Shadow Creek Dr Fresno, Ca 93730
NOTICE TO PATIENTSMedical doctors are licensed and regulated by the Medical Board of California. To check up on a license or to file a complaint go to www.mbc.ca.gov, email licensecheck@mbc.ca.gov, or call (800) 633-2322.
Contact
1-516-478-8304 Phone/Fax/Text
Email: admin@finsneuro.org (secure)
Notice to Patients: The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.